Neurones Return On Equity vs. Revenue
| NRO Stock | EUR 44.90 0.05 0.11% |
For Neurones profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Neurones to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Neurones utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Neurones's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Neurones over time as well as its relative position and ranking within its peers.
Neurones |
Neurones Revenue vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Neurones's current stock value. Our valuation model uses many indicators to compare Neurones value to that of its competitors to determine the firm's financial worth. Neurones is considered to be number one stock in return on equity category among its peers. It also is rated top company in revenue category among its peers totaling about 4,133,136,137 of Revenue per Return On Equity. Comparative valuation analysis is a catch-all model that can be used if you cannot value Neurones by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Neurones' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Neurones Revenue vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Neurones |
| = | 0.14 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Neurones |
| = | 579.88 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Neurones Revenue vs Competition
Neurones is rated top company in revenue category among its peers. Market size based on revenue of Information Technology industry is now estimated at about 1.37 Billion. Neurones totals roughly 579.88 Million in revenue claiming about 42% of equities under Information Technology industry.
Neurones Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Neurones, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Neurones will eventually generate negative long term returns. The profitability progress is the general direction of Neurones' change in net profit over the period of time. It can combine multiple indicators of Neurones, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Neurones S.A., an information technology services company, provides infrastructure, application, and consulting services in France and internationally. Neurones S.A. was founded in 1985 and is headquartered in Nanterre, France. NEURONES operates under Information Technology Services classification in France and is traded on Paris Stock Exchange. It employs 5160 people.
Neurones Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Neurones. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Neurones position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Neurones' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Neurones without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Manager Now
Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital |
| All Next | Launch Module |
Use Investing Themes to Complement your Neurones position
In addition to having Neurones in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Pharmaceutical Products Thematic Idea Now
Pharmaceutical Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Pharmaceutical Products theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Pharmaceutical Products Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Neurones Stock
To fully project Neurones' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Neurones at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Neurones' income statement, its balance sheet, and the statement of cash flows.